<DOC>
	<DOC>NCT02044653</DOC>
	<brief_summary>The primary objective of study is - Part A : To explore the optimal fixed starting dose and dosing interval of GX-E2 - Part B : To evaluate the proof of concept (POC) of GX-E2</brief_summary>
	<brief_title>Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)</brief_title>
	<detailed_description>The secondary objective of study is to evaluate: - change of red blood cell indices in anemic patients with chronic kidney disease receiving hemodialysis/peritoneal dialysis when administering GX-E2 intravenously/subcutaneously - change of reticulocyte indices in anemic patients with chronic kidney disease receiving hemodialysis/peritoneal dialysis when administering GX-E2 intravenously/subcutaneously - safety of GX-E2 when administering intravenously/subcutaneously - incidence of blood transfusion in anemic patients with chronic kidney disease receiving hemodialysis/peritoneal dialysis when administering GX-E2 intravenously/subcutaneously - Immunogenicity in anemic patients with chronic kidney disease receiving hemodialysis/peritoneal dialysis when administering GX-E2 intravenously/subcutaneously</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Written informed consent ≥18 yr of age Chronic Kidney diseases with hemodialysis, peritoneal dialysis Adequate transferrin saturation (≥20%), serum ferritin (≥100g/dl) Should have received Vitamine B12 ≥ 3 months before the first dose of study agent Should have received Folate ≥3 months before the first dose of study agent No erythropoietin (EPO) therapy within 2month before the planned first dose of GXE2 and Hb&lt;10g/dL or No EPO therapy within month before the planned first dose of GXE2 and Hb&lt;10g/dL Uncontrolled hypertension Uncontrolled arrhythmia History of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease) History of hypersensitivity to the study drug or to similar drug aspartate aminotransferase/alanine aminotransferase (ALT/AST) &gt; 3 times Upper Normal Limit of Normal (UNL) Absolute neutrophil count ≤ 1,500 per microliter (uL) Donation or loss of ≥400 milliliter (mL) of blood within 8 weeks prior to first dose Major surgery within 3 months Grand Mal epilepsy History of drug or alcohol abuse in the 6 months prior to Screening Participation in any clinical investigation in the 4 week period prior to dosing Refractory of erythropoiesis stimulating agent (ESA) treatment Systemic hematologic diseases (e.g. Pure red cell anemia, sickle cell anemia, myelodysplastic syndromes, hematologic malignancy, myeloma, hemolytic anemia)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Phase 2</keyword>
</DOC>